نتایج جستجو برای: tnbcs
تعداد نتایج: 265 فیلتر نتایج به سال:
PURPOSE Epidermal growth factor receptor (EGFR) is a targetable receptor frequently overexpressed in basal-like breast cancer, which comprises most triple-negative breast cancers (TNBCs), the only subtype without established targeted therapy. PATIENTS AND METHODS In this randomized phase II trial, patients with metastatic TNBC received anti-EGFR antibody cetuximab (400 mg/m(2) load then 250 m...
Triple Negative Breast Cancers (TNBC) is a heterogeneous disease at the molecular and clinical level with poor outcome. Molecular subclassification of TNBCs is essential for optimal use of current therapies and for development of new drugs. microRNAs (miRNA) are widely recognized as key players in cancer progression and drug resistance; investigation of their involvement in a TNBC cohort may re...
Triple-negative breast cancers (TNBCs) are aggressive and lack targeted therapies. Understanding how nutrients are used in TNBCs may provide new targets for therapeutic intervention. We demonstrate that the transcription factor c-Myc drives glucose metabolism in TNBC cells but does so by a previously unappreciated mechanism that involves direct repression of thioredoxin-interacting protein (TXN...
Triple-negative breast cancers (TNBCs) are heterogeneous cancers that present tumors without the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Because of the absence of these receptors, there are currently no known specific molecular targets for treatment, and although TNBC tumors are chemosensitive, prognosis is poor because this type ...
Antibody-mertansine (DM1) conjugates (AMCs) are among the very few active targeting therapeutics that are approved or clinically investigated for treating various cancers including metastatic breast cancer. However, none of the AMCs are effective for the treatment of triple-negative breast cancers (TNBCs). Here, we show that cRGD-decorated, redox-activatable micellar mertansine prodrug (cRGD-MM...
Triple-negative breast cancers (TNBC),which include the basallike and claudin-low disease subtypes, are aggressive malignancies for which effective therapeutic targets are lacking. NF-kB activation has an established role in breast malignancy, and it is higher in TNBC than other breast cancer subtypes. On this basis, we hypothesized that proteins derived from NF-kB target genes might be molecul...
Triple-negative breast cancers (TNBC),which include the basallike and claudin-low disease subtypes, are aggressive malignancies for which effective therapeutic targets are lacking. NF-kB activation has an established role in breast malignancy, and it is higher in TNBC than other breast cancer subtypes. On this basis, we hypothesized that proteins derived from NF-kB target genes might be molecul...
Background: Among the parameters that have a prognostic and/or predictive significance to therapeutic response, in case of breast carcinoma, study tumor-infiltrating lymphocytes carcinomas is emerging. The present aimed access clinicopathological profiles patients with primary carcinoma. Materials and Methods: Information was collected from archive Department Pathology, about invasive cancers d...
The Lewis X (Le(X)) antigen is a prognostic marker in certain solid tumors and has been proposed as a therapeutic target. Immunohistochemical analyses were performed to retrospectively examine the prognostic impact of Le(X) expression in 158 patients with triple-negative breast cancer (TNBC). Twenty-three (14.5%) patients were Le(X)-positive. Multivariate analysis showed that Le(X) positivity w...
DNA repair is a key determinant in the cellular response to therapy and tumor repair status could play an important role in tailoring patient therapy. Our goal was to evaluate the mRNA of 13 genes involved in different DNA repair pathways (base excision, nucleotide excision, homologous recombination, and Fanconi anemia) in paraffin embedded samples of triple negative breast cancer (TNBC) compar...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید